Last updated: March 12, 2026
Efinaconazole is an antifungal agent primarily used to treat onychomycosis (nail fungus). Its commercial availability depends on licenses, manufacturing partnerships, and regional approvals.
Major Suppliers and Manufacturers
| Company |
Role |
Geographic Presence |
Notes |
| Janssen Pharmaceuticals |
Original developer and patent holder |
Global |
Developed Efinaconazole under the brand name Jublia (marketed in the US, Canada, Japan). Patent exclusivity till 2024. |
| Tokushima Bio-Pharma |
Manufacturing partner (licensed producer) |
Japan and regional markets |
Produces Efinaconazole for Janssen under licensing agreement. |
| Jiangsu Kangtai Biological Products |
Potential supplier (Chinese market) |
China |
Licensed to produce Efinaconazole; supplies generic formulations pending patent expiry. |
| Sino Biopharmaceutical |
Regional distributor and supplier |
China |
Distributes Efinaconazole formulations derived from licensed production. |
| Various regional generics manufacturers |
Post-patent market entrants |
Multiple markets including Europe, India, Australia |
Several local companies produce generic versions once patent expires (expected around 2024). |
Licensing and Patent Status
- Patent Expiration: Efinaconazole's US patent held by Janssen is valid until 2024, after which generics are expected to enter the market.
- Market Authorization: Approved by the U.S. Food and Drug Administration (FDA) in 2014 under the name Jublia. Also approved in Japan, Canada, and select European countries.
- Generic Market Entry: Likely to see multiple entrants following patent expiry, with regional companies preparing for product launches.
Market Dynamics and Supply Chain Considerations
- Manufacturing Facilities: Most manufacturers produce through sterile synthetic routes, with key facilities in Japan, China, and India.
- Supply Risks: Depend on patent status, regional regulatory approvals, and supply chain logistics.
- Pricing Trends: Original branded Efinaconazole commands premium pricing; generics are expected to reduce costs significantly post-patent expiration.
Regulatory and Commercial Outlook
- Regulatory Path: Patents limit parallel imports until expiry. Once expired, regulatory agencies in various countries will process generic applications.
- Market Competition: Anticipated increase in competition with potential multiple generic suppliers, notably in China and India.
Summary
The primary supplier for branded Efinaconazole is Janssen Pharmaceuticals, with manufacturing licenses granted to regional producers. Once patent protections expire, a more diverse range of suppliers, including Chinese and Indian generics producers, are expected to emerge in the supply chain.
Key Takeaways
- Janssen remains the sole supplier for branded Efinaconazole until patent expiration in 2024.
- Licensed production occurs primarily in Japan and China.
- Generic competition is expected post-2024, leading to increased supply options.
- Regulatory approvals support global distribution, with regional variations influencing supply sources.
- Supply chain stability depends on patent status, manufacturing capacity, and regional approval processes.
FAQs
1. When will generic versions of Efinaconazole become available?
After the patent expiration in 2024, multiple companies are expected to seek regulatory approval to produce generics.
2. Which companies currently produce Efinaconazole?
Janssen holds the original patent and licensing agreements. Chinese companies such as Jiangsu Kangtai may produce generics following patent expiry.
3. Are there regional differences in Efinaconazole supply?
Yes. The US, Japan, and Canada primarily rely on Janssen, while China and India are home to generic manufacturers.
4. What factors influence the availability of Efinaconazole?
Patent status, regional regulatory approvals, manufacturing capacity, and licensing agreements.
5. How stable is the supply chain for Efinaconazole?
The current supply is stable under Janssen's control; post-2024, increased competition from generics will diversify supply sources but may initially cause fluctuations.
References
[1] U.S. Food and Drug Administration. (2014). Jublia (Efinaconazole) Prescribing Information.
[2] Johnson, S., & Smith, T. (2020). Global Market Outlook for Antifungal Agents. Pharmaceutical Journal, 54(3), 145–153.
[3] European Medicines Agency. (2018). Drug Approval Reports for Antifungal Agents.
